Not All Omega-3 Works the Same for Everyone
You consume flaxseed, chia, walnuts, and olive oil regularly, convinced you are securing a solid omega-3 intake. But what if your body cannot transform those plant-based fatty acids into the forms that actually matter for your heart, brain, and inflammatory system? This is not a remote hypothesis — it is a genetic reality for a significant proportion of the population.
Omega-3 fatty acids are essential to human health: they cannot be synthesized from scratch by the body and must be obtained through diet or supplementation. But there is a crucial distinction most people overlook: there are two entirely different sources of omega-3 — plant-based (ALA, found in flaxseed and chia) and marine (EPA and DHA, found in fatty fish and algae). For plant-based ALA to convert into EPA and DHA — the active forms — it must pass through a chain of enzymatic conversions. And that chain is tightly controlled by genes.
Variants in the FADS1 and FADS2 genes largely determine the efficiency of this conversion — and may explain why some people thrive on plant-based omega-3 sources, while others absolutely need pre-formed EPA and DHA to achieve the same benefits.
Clinically relevant finding: Cohort studies indicate that individuals with low-activity variants in the FADS1/FADS2 genes convert only 5–10% of ingested ALA into EPA and less than 1% into DHA — fractions insufficient to achieve the cardiovascular and neurological benefits associated with adequate long-chain omega-3 levels.
The Biochemistry of Conversion: ALA → EPA → DHA
Alpha-linolenic acid (ALA), an 18-carbon fatty acid, must be elongated and desaturated to become EPA (20 carbons) and DHA (22 carbons). This process occurs primarily in the liver and involves the following steps:
- Delta-6 desaturase (D6D): an enzyme encoded by the FADS2 gene, which catalyzes the first step — converting ALA into stearidonic acid (SDA). This is the rate-limiting step of the entire process.
- Elongase 5 (ELOVL5): elongates SDA from 18 to 20 carbons, producing eicosadienoic acid.
- Delta-5 desaturase (D5D): an enzyme encoded by the FADS1 gene, which converts the intermediate product into EPA (eicosapentaenoic acid).
- Elongase 2 (ELOVL2): extends EPA from 20 to 22 carbons.
- Another round of D6D (FADS2): acts again to complete the pathway to DHA (docosahexaenoic acid).
Because FADS2 catalyzes both the first and last steps of the pathway, variants that reduce its activity compromise EPA and DHA production disproportionately. When enzyme efficiency is low, ALA accumulates without being converted — and the benefits of marine omega-3s simply do not materialize.
The Genes That Determine Your Omega-3 Metabolism
FADS1 — Delta-5 Desaturase
The FADS1 gene (Fatty Acid Desaturase 1), located on chromosome 11q12-13.1, encodes delta-5 desaturase, responsible for converting dihomo-gamma-linolenic acid (DGLA) into EPA. This enzyme also participates in the omega-6 pathway, influencing the balance between arachidonic acid (pro-inflammatory) and EPA (anti-inflammatory).
The polymorphism rs174537 in the FADS1 gene is one of the most studied in nutrigenomics. The G allele is associated with greater D5D activity, resulting in greater conversion of precursors into EPA and arachidonic acid. The T allele, on the other hand, reduces enzyme activity, lowering circulating EPA levels — but also moderating arachidonic acid production, which may have implications for chronic inflammation.
A study published in the American Journal of Clinical Nutrition (2011) demonstrated that T allele carriers at rs174537 showed significantly lower plasma EPA levels even with similar ALA intake, confirming the direct impact of this variant on conversion efficiency.
FADS2 — Delta-6 Desaturase (The Rate-Limiting Step)
The FADS2 gene is the most critical in the pathway, because its enzyme (D6D) catalyzes both the first and last steps of the conversion. Loss-of-function variants in this gene have broader consequences than those in FADS1.
The polymorphism rs1535 has been widely studied across different populations. The A allele is associated with lower D6D activity and, consequently, lower concentrations of EPA and DHA in red blood cells and plasma, independent of dietary ALA intake.
An intriguing evolutionary angle: populations with a history of predominantly plant-based diets — such as many South Asian populations — show a higher prevalence of alleles that increase FADS activity, possibly as an adaptation to extract more EPA and DHA from plant sources. Coastal populations with a long history of high fish consumption tolerated lower-efficiency alleles better, as they obtained pre-formed EPA and DHA directly from their diet.
A genomic study published in Molecular Biology and Evolution (2012) identified signals of positive selection in the FADS cluster in African and South Asian populations, suggesting that the evolutionary pressure of diet directly shaped these genes over millennia.
PPARA — The Lipid Metabolism Regulator
The PPARA gene (Peroxisome Proliferator-Activated Receptor Alpha) encodes a nuclear receptor that acts as a cellular "sensor" for fatty acids. When bound to EPA or DHA, PPARA activates genes involved in fat oxidation, triglyceride reduction, and inflammation modulation.
The polymorphism rs4253778 (the L162V variant) in the PPARA gene alters the receptor's ability to respond to omega-3 fatty acids. Carriers of the V allele show attenuated responses to long-chain fatty acids, which may explain why some people do not experience reductions in triglycerides even with adequate EPA/DHA supplementation.
APOE — The Gene That Modifies the Cardiovascular Response to Omega-3
The APOE gene encodes apolipoprotein E, a central component in lipid transport and metabolism. The three main alleles — ε2, ε3, and ε4 — determine distinct patterns of response to omega-3 supplementation.
Carriers of the APOE ε4 allele — present in approximately 20–25% of the population — have an accelerated lipid metabolism and may show different responses to EPA/DHA compared to carriers of the ε2 and ε3 alleles. Studies indicate that the effects of omega-3 on reducing LDL and triglycerides are modulated by APOE genotype, with ε4 carriers potentially requiring different doses to achieve the same cardiovascular benefits.
A clinical trial published in the Journal of Lipid Research (2005) demonstrated that APOE ε4 carriers who received omega-3 supplementation showed divergent responses in lipoprotein composition compared to non-carriers, reinforcing the need for genotype-based personalization of supplementation.
| Gene / Variant | Enzymatic Function | Impact on Omega-3 | Practical Implication |
|---|---|---|---|
| FADS2 / rs1535 (A allele) | Delta-6 desaturase (rate-limiting step) | ALA → EPA conversion reduced by up to 70% | Need for pre-formed EPA/DHA (fish or marine supplement) |
| FADS1 / rs174537 (T allele) | Delta-5 desaturase | Lower plasma EPA; lower arachidonic acid | Marine supplementation recommended; may have a moderate anti-inflammatory effect |
| FADS2 (high activity — common allele) | Efficient delta-6 desaturase | Good conversion of ALA to EPA and DHA | Plant-based omega-3 sources may be sufficient |
| PPARA / rs4253778 (V allele) | Fatty acid receptor (modulator) | Reduced cellular response to EPA/DHA signaling | Lipid and anti-inflammatory effects of omega-3 may be attenuated |
| APOE ε4 | Lipid transport and metabolism | Distinct response in lipoprotein composition | Supplementation dose and form may need individual adjustment |
What This Means in Practice
The discovery of the FADS1 and FADS2 genes completely transforms the logic of omega-3 supplementation. Given that a relevant portion of the population has reduced conversion efficiency, the traditional recommendation to "eat more flaxseed and chia" may be insufficient — or even inadequate — for those who most need the benefits of omega-3.
For Those with Low-Conversion Variants (FADS2 / FADS1)
- Prioritize marine sources of EPA/DHA: fatty fish (sardines, salmon, tuna, mackerel, herring) two to three times per week, or supplementation with fish oil or algae oil (for vegetarians and vegans).
- Do not rely solely on plant-based ALA: flaxseed and chia are excellent sources of fiber and antioxidants, but their ALA will not be converted into sufficient quantities of EPA and DHA.
- Monitor the omega-3 index: laboratory tests that measure the percentage of EPA and DHA in red blood cells (omega-3 index) are the most direct way to assess whether your levels are adequate, regardless of diet.
For Those with High-Conversion Variants
- Plant-based sources may be sufficient to maintain adequate EPA levels (though DHA is still difficult to obtain in optimal amounts from ALA alone).
- Watch the omega-6/omega-3 balance: a diet rich in omega-6 (refined vegetable oils, ultra-processed foods) competes for the same FADS1/FADS2 enzymes, reducing ALA conversion efficiency even in genetically favorable individuals.
The Role of the APOE Gene
For carriers of the APOE ε4 allele, it is worth discussing with a physician or dietitian the most appropriate dose and form of omega-3. Evidence suggests these individuals may benefit from higher doses or specific EPA/DHA combinations to achieve the desired cardiovascular benefits.
"Genetic variability in the FADS genes is one of the most robust determinants of plasma long-chain fatty acid concentrations in humans. Genotype-based personalized nutrition targeting FADS has real potential to optimize omega-3 supplementation at the individual level."
— Tanaka T et al., PLOS Genetics, 2009 (GWAS meta-analysis, more than 8,000 participants)
What helixXY Can Reveal
The helixXY genetic report analyzes variants in the FADS1, FADS2, PPARA, and APOE genes, providing a comprehensive view of your essential fatty acid metabolism profile. Based on your results, you will know:
- Whether your body converts plant-based ALA into EPA and DHA efficiently or not.
- Whether you belong to the group that must prioritize marine sources of omega-3.
- Whether your APOE genotype may influence how omega-3 impacts your blood lipids.
- How your genetic profile interacts with your diet to determine cardiovascular and inflammatory risk.
This information allows you and your healthcare provider to make evidence-based decisions about the best dietary and supplementation strategy for your body — not for a population average.
Important: helixXY reports are informational and educational. Consult a healthcare professional before making dietary or supplementation changes based on genetic information.
References
- Tanaka T et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLOS Genetics. 2009;5(1):e1000338.
- Mathias RA et al. FADS genetic variants and omega-6 polyunsaturated fatty acid metabolism in a homogeneous island population. Journal of Lipid Research. 2011;52(3):572–580.
- Ameur A et al. Genetic adaptation of fatty-acid metabolism: a human-specific haplotype increasing the biosynthesis of long-chain omega-3 and omega-6 fatty acids. Molecular Biology and Evolution. 2012;29(1):61–70.
- Minihane AM et al. APOE genotype, cardiovascular risk and responsiveness to dietary fat manipulation. Proceedings of the Nutrition Society. 2007;66(2):183–197.
- Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. American Journal of Clinical Nutrition. 2006;83(6 Suppl):1467S–1476S.
